307 related articles for article (PubMed ID: 15373015)
21. Optimal selection of individuals for BRCA mutation testing.
Evans DG; Lalloo F; Eccles D
J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
[No Abstract] [Full Text] [Related]
22. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
[No Abstract] [Full Text] [Related]
23. DNA testing. Genetic screen misses mutations in women at high risk of breast cancer.
Stokstad E
Science; 2006 Mar; 311(5769):1847. PubMed ID: 16574828
[No Abstract] [Full Text] [Related]
24. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
26. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
27. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
28. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
29. Women with family breast cancer history have no increased risk of ovarian cancer.
Health News; 2006 Feb; 12(2):9. PubMed ID: 16456923
[No Abstract] [Full Text] [Related]
30. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
31. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
Narod SA; Rodríguez AA
Salud Publica Mex; 2011; 53(5):420-9. PubMed ID: 22218796
[TBL] [Abstract][Full Text] [Related]
32. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
33. [Susceptibility genes of familial breast cancer in Finland].
Nevanlinna H; Kallioniemi OP
Duodecim; 1999; 115(21):2365-74. PubMed ID: 11973868
[No Abstract] [Full Text] [Related]
34. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Woodward AM; Davis TA; Silva AG; Kirk JA; Leary JA;
J Med Genet; 2005 May; 42(5):e31. PubMed ID: 15863663
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
36. [Hereditary breast cancer: treatment and prevention].
Ejlertsen B; Gerdes AM
Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
[TBL] [Abstract][Full Text] [Related]
37. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
38. Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
Mark HF; McGowan KD
Cytobios; 1996; 87(351):229-35. PubMed ID: 9214724
[TBL] [Abstract][Full Text] [Related]
39. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
40. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
